Similar articles

• [Pathogenesis of rheumatoid arthritis].

  Alvaro-Gracia Alvaro JM. Alvaro-Gracia Alvaro JM. Rev Clin Esp. 2000 May;200 Monog 1:25-31. Rev Clin Esp. 2000. PMID: 10901023 Review. Spanish. No abstract available.
• Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis.

  DeLuca P, Rothman D, Zurier RB. DeLuca P, et al. Rheum Dis Clin North Am. 1995 Aug;21(3):759-77. Rheum Dis Clin North Am. 1995. PMID: 8619098 Review.
• [High-dose immunoglobulin therapy of rheumatoid arthritis].

  Horneff G, Schwab J, Holtz N, Kalden JR, Burmester GR. Horneff G, et al. Infusionsther Transfusionsmed. 1993 Apr;20 Suppl 1:110-5; discussion 116-7. Infusionsther Transfusionsmed. 1993. PMID: 8499738 German.
• Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.

  Hahn G, Stuhlmüller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR. Hahn G, et al. J Clin Invest. 1993 Mar;91(3):862-70. doi: 10.1172/JCI116307. J Clin Invest. 1993. PMID: 8450066 Free PMC article.
• [Therapy with oral type II collagen as a new possibility of selective immunosuppression in therapy of rheumatoid arthritis].

  Sieper J, Mitchison AN. Sieper J, et al. Z Rheumatol. 1994 Mar-Apr;53(2):53-8. Z Rheumatol. 1994. PMID: 8023585 Review. German.